ArticleThe journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians2016
Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD).
Article in The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 51 citations in OpenAlex.
- Maternal circulating sFlt-1/placental growth factor is a biomarker of fetal death associated with placental lesions of maternal vascular malperfusion.Journal of perinatal medicine · 2026Article
- Similar Spatial Expression of Immune-Related Proteins in SARS-CoV-2 Placentitis and Chronic Histiocytic Intervillositis.European journal of immunology · 2025Article
- Placental lesions in systemic lupus erythematosus pregnancies associated with small for gestational age infants.Rheumatology (Oxford, England) · 2024Article
- Long-term neurodevelopmental follow-up of children exposed to pravastatin in utero.American journal of obstetrics and gynecology · 2023Article
- Preeclampsia at term can be classified into 2 clusters with different clinical characteristics and outcomes based on angiogenic biomarkers in maternal blood.American journal of obstetrics and gynecology · 2023Article
- Human Plasma Proteome During Normal Pregnancy.Journal of proteome research · 2022Article
- Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology.American journal of obstetrics and gynecology · 2022Article
- The role of statins in the prevention of preeclampsia.American journal of obstetrics and gynecology · 2022Review
- Chronic Inflammatory Placental Disorders Associated With Recurrent Adverse Pregnancy Outcome.Frontiers in immunology · 2022Review
- Fetal akinesia deformation sequence and massive perivillous fibrin deposition resulting in fetal death in six fetuses from one consanguineous couple, including literature review.Molecular genetics & genomic medicine · 2021Article
- Decreased USP2a Expression Inhibits Trophoblast Invasion and Associates With Recurrent Miscarriage.Frontiers in immunology · 2021Article
- Modelling preeclampsia: a comparative analysis of the common human trophoblast cell lines.FASEB bioAdvances · 2021Article
- CXCL5 Downregulation in Villous Tissue Is Correlated With Recurrent Spontaneous Abortion.Frontiers in immunology · 2021Article
- Prevention of preeclampsia.Seminars in fetal & neonatal medicine · 2020Review
- Follow-up and management of recurrent pregnancy losses due to massive perivillous fibrinoid deposition.Obstetric medicine · 2018Article
- Different Effects of Pravastatin on Preeclampsia-like Symptoms in Different Mouse Models.Chinese medical journal · 2018Article
- The prediction of fetal death with a simple maternal blood test at 20-24 weeks: a role for angiogenic index-1 (PlGF/sVEGFR-1 ratio).American journal of obstetrics and gynecology · 2017Article
- Fetal death: an extreme manifestation of maternal anti-fetal rejection.Journal of perinatal medicine · 2017Article
- The maternal plasma proteome changes as a function of gestational age in normal pregnancy: a longitudinal study.American journal of obstetrics and gynecology · 2017Article
- Should We Add Pravastatin to Aspirin for Preeclampsia Prevention in High-risk Women?Clinical obstetrics and gynecology · 2017Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
Abstract
Massive perivillous fibrin deposition of the placenta (MPFD) or maternal floor infarction (MFI) is a serious condition associated with recurrent complications including fetal death and severe fetal growth restriction. There is no method to evaluate the risk of adverse outcome in subsequent pregnancies, or effective prevention. Recent observations suggest that MFI is characterized by an imbalance in angiogenic/anti-angiogenic factors in early pregnancy; therefore, determination of these biomarkers may identify the patient at risk for recurrence. We report the case of a pregnant woman with a history of four consecutive pregnancy losses, the last of which was affected by MFI. Abnormalities of the anti-angiogenic factor, sVEGFR-1, and soluble endoglin (sEng) were detected early in the index pregnancy, and treatment with pravastatin corrected the abnormalities. Treatment resulted in a live birth infant at 34 weeks of gestation who had normal biometric parameters and developmental milestones at the age of 2. This is the first reported successful use of pravastatin to reverse an angiogenic/anti-angiogenic imbalance and prevent fetal death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.